Ori Gutwerg Sells 2,772 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Ori Gutwerg sold 2,772 shares of ANI Pharmaceuticals stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $79.50, for a total value of $220,374.00. Following the sale, the senior vice president directly owned 78,696 shares of the company’s stock, valued at approximately $6,256,332. This represents a 3.40% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Ori Gutwerg also recently made the following trade(s):

• On Tuesday, March 3rd, Ori Gutwerg sold 2,060 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $76.50, for a total value of $157,590.00.

ANI Pharmaceuticals Stock Down 1.6%

ANIP stock opened at $79.58 on Friday. The firm’s fifty day simple moving average is $77.26 and its 200-day simple moving average is $80.50. The company has a market capitalization of $1.78 billion, a P/E ratio of 20.15 and a beta of 0.46. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.12 and a quick ratio of 2.52. ANI Pharmaceuticals, Inc. has a 12 month low of $56.71 and a 12 month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm had revenue of $237.46 million during the quarter, compared to analysts’ expectations of $207.63 million. During the same period in the previous year, the business posted $1.70 EPS. The business’s revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 7.73 earnings per share for the current year.

ANI Pharmaceuticals News Summary

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals posted a strong first quarter, with EPS of $2.05 beating estimates of $1.28 and revenue of $237.46 million topping expectations, while management also guided FY2026 EPS to $9.19-$9.69, reinforcing the company’s growth story.
• Positive Sentiment: Analyst sentiment remains favorable, with recent upgrades and a consensus “Moderate Buy” rating plus an average price target above the current trading range, which can support longer-term confidence in ANIP.
• Neutral Sentiment: ANI Pharmaceuticals updated its investor presentation and highlighted non-GAAP metrics, a routine corporate communication that does not appear to materially change the near-term outlook. ANI Pharmaceuticals Updates Investor Presentation, Highlights Non-GAAP Metrics
• Negative Sentiment: CEO Nikhil Lalwani sold 55,000 shares, and other executives and directors also trimmed holdings, including Patrick D. Walsh, Meredith Cook, Ori Gutwerg, and Thomas Andrew Rowland; heavy insider selling can weigh on sentiment even when some trades are pre-planned.
• Negative Sentiment: A separate filing reported that Global Alpha sold 229,000 ANIP shares worth about $17.9 million, adding to concerns that a large investor may be reducing exposure. Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million

Analysts Set New Price Targets

A number of equities analysts have weighed in on ANIP shares. Guggenheim upped their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 15th. Finally, Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $107.33.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Hantz Financial Services Inc. boosted its stake in ANI Pharmaceuticals by 202.6% during the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after buying an additional 237 shares during the period. KBC Group NV purchased a new position in ANI Pharmaceuticals during the first quarter worth about $28,000. Advisors Asset Management Inc. purchased a new position in ANI Pharmaceuticals during the first quarter worth about $28,000. Kemnay Advisory Services Inc. purchased a new position in ANI Pharmaceuticals during the fourth quarter worth about $48,000. Finally, State of Wyoming purchased a new position in ANI Pharmaceuticals during the second quarter worth about $50,000. Hedge funds and other institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.